<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016522</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00008855</org_study_id>
    <nct_id>NCT01016522</nct_id>
    <nct_alias>NCT01035710</nct_alias>
  </id_info>
  <brief_title>Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Safety and Tolerability of the Ketogenic Diet in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutricia North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to see if the ketogenic diet (which is high in fat and low in
      carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are
      fed through a gastrostomy tube. This is not a study to see if ketogenic diets are effective
      in the treatment of ALS.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study will determine if humans with ALS fed a strictly controlled diet designed to generate large amounts of ketones is safe and well-tolerated without evidence of weight loss or other adverse effect</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in motor function, strength, fatigue, body fat and cognitive function</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>KetoCal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KetoCal tube feeding formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KetoCal</intervention_name>
    <description>Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates</description>
    <arm_group_label>KetoCal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Familial or sporadic ALS diagnosed as probable, laboratory-supported probable or
             definite according to the World Federation of Neurology El Escorial criteria

          2. Age 18 or older

          3. Capable of providing informed consent and complying with trial procedures

          4. Gastrostomy tube in place for the prior month

          5. Appel ALS score less than 100

          6. Able to stand on a scale with assistance

          7. For patients with Appel ALS scores greater than 80, availability of caregiver who is
             willing and able to:

               -  Prepare, administer and log tube feeds

               -  Check and log gastric residuals

               -  Assist with weighing subject at home if necessary

          8. Willing to chart food intake during the six-month study

          9. Patients either not taking Riluzole (Rilutek) or Minocycline or on a stable dose of
             these for 30 days

         10. Not taking Coenzyme Q10 or on a stable dose and brand for 30 days

         11. Absence of exclusion criteria

        Exclusion Criteria:

          1. Forced vital capacity &lt;50% of predicted

          2. Dependence on mechanical ventilation for more than 12 hours per day

          3. Exposure to any experimental agent within 30 days of onset of this protocol

          4. Women who are pregnant or planning to become pregnant

          5. Women of childbearing potential not practicing contraception

          6. Enrollment in another research study within 30 days of or during this trial

          7. Mini-Mental State Exam (MMSE) score &lt;20

          8. Patients with symptomatic cardiac disease or hypercholesterolemia

          9. Patients with myocardial infarction within 6 months of this trial

         10. Renal dysfunction defined as BUN and creatinine &gt;2XULN

         11. Known mitochondrial disease

         12. BMI&lt;18.5

         13. Prior use of a 4:1 ketogenic diet or Atkins diet within 1 month of this trial

         14. Impaired liver function, defined as AST or ALT of 3 X ULN

         15. Patients who have a pacemaker or other internal electronic medical device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins ALS Clinic</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Vinay Chaudhry</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Ketogenic Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

